Physician profile
Michael D Cohen
NPI 1871517995
$3,078.99
in general payments reported to CMS, 2019-2025
14 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $49.78 · 2021: $23.32 · 2022: $650 · 2023: $775 · 2024: $722 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.90 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $763.75 | 2019-2025 | Biktarvy |
| Paratek Pharmaceuticals, INC. | $748.87 | 2022-2025 | Nuzyra |
| Shionogi INC | $360.22 | 2022-2024 | Fetroja |
| Insmed, INC. | $326.43 | 2019-2025 | Arikayce |
| La Jolla Pharmaceutical Company | $164.42 | 2023-2025 | Zevtera, Xerava |
| Merck Sharp & Dohme LLC | $161.66 | 2020-2025 | Pifeltro, Delstrigo, Dificid |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2023 | Andexxa |
| Janssen Pharmaceuticals, INC | $124.99 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.97 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $90.06 | 2019 | |
| Abbvie INC. | $50.04 | 2021-2023 | Teflaro |
| Janssen Biotech, INC. | $30.59 | 2019 | |
| Amgen INC. | $21.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.